(0.33%) 5 116.92 points
(0.32%) 38 364 points
(0.38%) 15 988 points
(-0.97%) $83.04
(5.51%) $2.03
(0.31%) $2 354.50
(0.45%) $27.66
(4.12%) $960.10
(-0.26%) $0.932
(-0.44%) $10.98
(-0.57%) $0.796
(1.66%) $93.40
@ $23.86
発行日: 15 2月 2024 @ 05:16
リターン: -54.92%
前回のシグナル: 2月 15 - 00:40
前回のシグナル:
リターン: 0.08 %
Live Chart Being Loaded With Signals
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases...
Stats | |
---|---|
本日の出来高 | 2.33M |
平均出来高 | 1.04M |
時価総額 | 503.39M |
EPS | $0 ( 2024-03-21 ) |
次の収益日 | ( $-0.480 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.52 |
ATR14 | $0.0330 (0.31%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-01 | Gerard Michael | Buy | 100 000 | Stock Option (Right to Buy) |
2024-03-01 | Chang David J. | Buy | 130 000 | Stock Option (Right to Buy) |
2024-03-01 | Nichtberger Steven | Buy | 353 000 | Stock Option (Right to Buy) |
2024-03-01 | Marda Anup | Buy | 130 000 | Stock Option (Right to Buy) |
2024-03-01 | Das Arun | Buy | 100 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
82.25 |
Last 97 transactions |
Buy: 4 947 826 | Sell: 1 979 584 |
ボリューム 相関
Cabaletta Bio Inc 相関
10 最も負の相関 | |
---|---|
RMRM | -0.919 |
NEXI | -0.917 |
MARA | -0.914 |
SVAC | -0.908 |
ITRM | -0.9 |
PAIC | -0.898 |
SRZN | -0.892 |
NOTV | -0.887 |
LPTX | -0.887 |
PRVA | -0.886 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Cabaletta Bio Inc 相関 - 通貨/商品
Cabaletta Bio Inc 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-1.43M (0.00 %) |
EPS: | $-1.650 |
FY | 2023 |
収益: | $0 |
総利益: | $-1.43M (0.00 %) |
EPS: | $-1.650 |
FY | 2022 |
収益: | $0 |
総利益: | $-3.68M (0.00 %) |
EPS: | $-1.770 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.15 |
Financial Reports:
No articles found.
Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。